Abstract： Objective： To systematically evaluate the clinical effect and safety of Danshen injection combined with alprostadil for diabetic nephropathy(DN). Methods： Randomized Controlled Trials(RCT) of Danshen injection combined with alprostadil for DN were carried out by computer retrieval on China National Knowledge Infrastructure(CNKI)， Wanfang Database(WANFANG)， VIP Chinese Medical Journal Database(CMJD)， China Biomedical Literature Database(CBM)， Cochrane Library and PubMed Database from their constructions to June 1，2019. Literature screening，data extraction and quality evaluation of literature were performed by two researchers independently and respectively. RevMan5.3 software was applied to carry out meta analysis. Results：Finally，9 RCTs were included，with a total of 742 patients. When compared with the indexes of clinical effective rate，creatinine(Cr)，blood urea nitrogen(BUN)，total cholesterol(TC)，triglyceride(TG)，lowdensity lipoprotein(LDL)， high- density lipoprotein(HDL) and urinary albumin excretion rate(UAER)， the therapy of Danshen injection combined with alprostadil for DN was better than simple application of alprostadil. Conclusion： The therapy of Danshen injection combined with alprostadil for DN has better clinical effect and safety than simple application of alprostadil.